Thorac cardiovasc Surg 2018; 66(04): 278-286
DOI: 10.1055/s-0036-1583525
Review Article
Georg Thieme Verlag KG Stuttgart · New York

The Value of Circulating Biomarkers in Bicuspid Aortic Valve-Associated Aortopathy

Shiho Naito
Department of Cardiac Surgery, Central Hospital Bad Berka, Bad Berka, Germany
,
Mathias Hillebrand
Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany
,
Alexander Martin Justus Bernhardt
Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
Annika Jagodzinski
Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany
,
Lenard Conradi
Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
Christian Detter
Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
Karsten Sydow
Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany
,
Hermann Reichenspurner
Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
Yskert von Kodolitsch
Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany
,
Evaldas Girdauskas
Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
› Author Affiliations
Further Information

Publication History

06 January 2016

14 March 2016

Publication Date:
05 May 2016 (eFirst)

Abstract

Traditional risk stratification model of bicuspid aortic valve (BAV) aortopathy is based on measurement of maximal cross-sectional aortic diameter, definition of proximal aortic shape, and aortic stiffness/elasticity parameters. However, conventional imaging-based criteria are unable to provide reliable information regarding the risk stratification in BAV aortopathy, especially considering the heterogeneous nature of BAV disease. Given those limitations of conventional imaging, there is a growing clinical interest to use circulating biomarkers in the screening process for thoracic aortic aneurysms as well as in the risk-assessment algorithms. We aimed to systematically review currently available biomarkers, which may be of value to predict the natural evolution of aortopathy in individuals with BAV.